Dr. Antonio Anzueto, Professor of Medicine and Section Chief of Pulmonary at South Texas Veterans Healthcare System, an affiliated Institution with the University of Texas Health San Antonio, discusses the 2023 Global Obstruction Lung Disease (GOLD) Report that recommends long-acting muscarinic antagonist (LAMA), long-acting beta agonist (LABA), or LAMA+LABA therapy as a first-line treatment for most patients with COPD, regardless of exacerbation risk.
Dr. Antonio Anzueto is a Professor of Medicine and Section Chief of Pulmonary at South Texas Veterans Healthcare System, an affiliated Institution with the University of Texas Health San Antonio and specializes in Pulmonary Medicine and Critical Care.
He completed his undergraduate studies at Colegio Liceo Javier in 1972. He received his Doctor of Medicine in 1979 at the University of San Carlos, in Guatemala City. In 1989, he completed his internship and residency in internal medicine followed by Pulmonary Medicine/ Critical Fellowship at University of Texas, Health, San Antonio.
He is an active member of the American Thoracic Society, American College of Chest Physicians (CHEST), European Respiratory Society, Latin American Thoracic Society (ALAT), Global Obstruction Lung Disease (GOLD).
Dr. Anzueto and his Pulmonary research group are currently conducting clinical studies that involve treating conditions that range from chronic obstructive pulmonary disease (COPD), pneumonia, acute respiratory distress/injury, to septic shock.